Improving the Treatment of Chronic Spontaneous Urticaria: What Does the Future Hold?

Program Overview

In this activity, a panel of experts discuss the current guideline-recommended treatment approach to chronic spontaneous urticaria (CSU), with a focus on treatment of patients with refractory disease requiring third-line therapy. The panel will also discuss advances in understanding the pathogenesis of disease, the role of type 2 inflammation, and emerging therapies.

Credit Expired

Target Audience

This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
  • Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
  • Assess current safety and efficacy data on emerging therapies for the treatment of CSU

Activity Faculty


Jonathan A. Bernstein, MD

Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH


Autumn Burnette, MD, FACAAI

Assistant Professor, Division of Allergy and Immunology
Howard University Hospital
Washington, DC

Faculty_David M Lang_hi-res_600x620px (1)

David M. Lang, MD

Professor and Chair, Medicine
Department of Allergy and Clinical Immunology
Respiratory Institute
Cleveland, OH


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources